x
07/2020 Ventures

Resistell receives EIC Accelerator Grant

In times of COVID-19, the signs are more in favor of saving than investing. Especially life sciences start-ups can therefore only develop or test their life-saving technologies at a slower pace. This makes it all the more important for us to support young companies in the current situation. We are therefore very pleased that the European Commission has the same ambition and supports Resistell in the generation of an improved method for detecting antibiotic resistance with the Enhanced European Innovation Council (EIC) Accelerator Grant totaling 2.5 million euros.

More information can be found in the press release under the following link.

More about Resistell

06/2020 Ventures

INVESTMENT IN CODE INTELLIGENCE

OCCIDENT invests in the Bonn-based start-up Code Intelligence. Together with LBBW Venture Capital und investiere, a very good consortium has been formed for the Pre-Series A financing round. Code Intelligence enables software security testing through innovative fuzzing already in the development phase of software. Using CI Fuzz, vulnerabilities can be detected earlier and fully automatically, allowing developers to analyze errors faster and to fix them at the code base. Thus CI Fuzz drastically improves the stability and reliability of software.

More information can be found in the press release under the following link.

More about Code Intelligence

06/2020 Ventures

FOLLOW-UP INVESTMENT IN ADVANCECOR

For the second time, OCCIDENT is participating in a financing round for the Munich-based biotech company advanceCOR GmbH, which specializes in the personalized therapy of cardiovascular diseases. The unique feature is the lead project Revacept® developed by advanceCOR, which does not interfere with the body’s own blood coagulation, but acts directly at the site of vascular damage. The active ingredient has already been successfully tested in two clinical trials. With the new investment, advanceCOR now wants to further accelerate the development of Revacept®.

For more information please read the press release under the following link.

More about advanceCOR

05/2020 Ventures

GNA RECEIVES FUNDING FOR CORONA TEST

Again we have great news from our portfolio company GNA Biosolutions. The Innovative Medicines Initiative (IMI), a partnership between the European Union and the European pharmaceutical industry, has committed financial support to GNA to promote approaches to the diagnosis and treatment of COVID-19.
The IMI selected GNA as one of eight institutions and the only German lead company out of 144 proposals. The decision is based on the quality and speed in which patients can be tested for COVID-19 thanks to the disruptive technology. Due to GNA’s molecular diagnostic method using PCA, patients could be tested almost anywhere in laboratory quality and within 15 to 20 minutes they would have clarity if they were suffering from corona virus.

For more information please see an article by AktienCheck (link) and the press release of IMI (link).

More about GNA

05/2020 Team

New Marketing & Communications Manager

OCCIDENT welcomes Pia Hoppenberg to the team. After graduating in media communications and working in the PR sector for several years, Pia joins the OCCIDENT team as the new Marketing & Communications Manager in the Munich office.

04/2020 Ventures

GNA has developed corona test

Our Munich-based portfolio company GNA Biosolutions is making its contribution to the fight against the corona virus and is also supported by the Bavarian Ministry of Economic Affairs in order to enable the market launch of the mobile test device within 8-12 weeks. GNA Biosolutions uses a novel detection method, which provides a reliable result regarding a possible COVID-19 disease within 15 minutes. With 1,000 devices about 300,000 tests could be performed daily.
In addition to the current challenges, the rapid diagnosis of highly infectious diseases will continue to provide a good database for the future in order to identify pandemic risks at an early stage and initiate appropriate measures.

More information can be found in the article in Süddeutsche Zeitung (text in German) under the following link.

More about GNA

03/2020 Group

OCCIDENT – digital and financially strong

As a company that has been digital for years, the conversion to home office in the course of COVID-19 was not difficult for us. Since mid-March, we have been keeping our physical distance responsibly and considerately, but we are still making a digital effort to promote interpersonal exchange and cohesion during the crisis. During this time, it becomes particularly clear how important the digitalization of our processes and the solidarity towards our fellow human beings are.

For years, OCCIDENT has been investing in start-ups that make digital and medical progress possible and thus represent added value for society. As a financially strong and entrepreneurial investor, we will continue to support start-ups. Especially in the current crisis, we take our responsibility seriously and continue to be a trustworthy partner for visionary founders.

Stay healthy and take care of yourself!

02/2020 Ventures

Follow-up Investment in Lunaphore

Already for the third time, Occident participates in a financing round for the Swiss diagnostics company Lunaphore, which revolutionizes tumor diagnostics with its technology. Following the successful market launch of LabSat, the new funds will flow into the company’s growth and internationalization, as well as into new innovations.

More information can be found in the press release under the following link.

More about Lunaphore

Show more